{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:34Z","timestamp":1772166214458,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of anti-tumor necrosis factor-alpha (TNF\u03b1: etanercept [Etanercept \u00ae]) therapy on adrenal activity in juvenile idiopathic arthritis (JIA) .<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Eleven JIA patients aged 12\u2009\u00b1\u20096.2 years with a disease duration of 6.3\u2009\u00b1\u20095.2 years were enrolled. They were treated once weekly with etanercept (0.8\u00a0mg\/kg) for 3\u2009\u00b1\u20092.8 years. Urine samples for gas chromatography-mass spectrometry steroid hormone analysis were collected before, and 1 and 3 days after etanercept injection and compared to age- and sex-matched healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The levels of 21 of the 31 metabolites were low before etanercept treatment. Those 21 metabolites included 4 C19 steroids (androgens), 5\u00a0C C21 steroid hormone intermediates, 10 cortisol metabolites, and 2 corticosterone metabolites. One day after treatment, only 5 of the 21 metabolite levels remained low. They included 2 C19 metabolites, 2 C21 steroid metabolites and 1 cortisol metabolite \u03b2 \u2013Cortol (\u03b2-Cl). Three days after treatment, the only metabolites levels that continued to be low were 2 C19 metabolite, 2 C21 steroid hormone intermediates and 1 cortisol metabolite \u03b1-Cortol (a-Cl), while the remaining 15 metabolites had already normalized after 1\u00a0day. Dehydroepiandrosterone-sulfate and 17-hydroxypregnenolone metabolite levels were the last ones to recover. Urinary metabolite ratios reflecting cytochrome P450 CYP21A2 (21-hydroxylase) and 11\u03b2-hydroxysteroid dehydrogenase type 2 (11\u03b2-HSD2) enzymatic activitieswere lower in JIA patients than in controls, although significant was not reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Almost all of the pre-etanercept treatment cortisol urinary metabolite levels were significantly lower than normal, and almost all rose to normal values by 1\u00a0day after treatment. The therapeutic effect of anti-TNF\u03b1 treatment in JIA may be related to its effect on the restoration of adrenal function and cortisol levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-023-00813-y","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T06:03:57Z","timestamp":1681279437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-7327","authenticated-orcid":false,"given":"Yonatan Butbul","family":"Aviel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Keinan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela F.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan A.","family":"Wudy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dov","family":"Tiosano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"813_CR1","doi-asserted-by":"crossref","unstructured":"Arend WP. Physiology of cytokine pathways in rheumatoid arthritis.Arthritis Rheum. 2001 Feb;45(1):101\u20136.","DOI":"10.1002\/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7"},{"key":"813_CR2","doi-asserted-by":"crossref","unstructured":"Ivashkiv LB. Cytokine expression and cell activation in inflammatory arthritis [Internet]. Vol.\u00a063, Advances in Immunology. Academic Press Inc.; 1996 [cited 2020 Mar 21]. p.\u00a0337\u201376. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8787634","DOI":"10.1016\/S0065-2776(08)60859-7"},{"key":"813_CR3","unstructured":"Sp\u00eerchez M, Sama\u015fca G, Iancu M, Bolba C, Miu N. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab [Internet]. 2012 [cited 2020 Mar 21];58(3\u20134):253\u201360. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22582498"},{"key":"813_CR4","doi-asserted-by":"crossref","unstructured":"Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: Implications for pathophysiology and therapeutic management [Internet]. Vol.\u00a056, Arthritis and Rheumatism. Arthritis Rheum; 2007 [cited 2021 May 24]. p.\u00a0399\u2013408. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17265475\/","DOI":"10.1002\/art.22368"},{"key":"813_CR5","doi-asserted-by":"crossref","unstructured":"Straub RH, Paimela L, Peltomaa R, Sch\u00f6lmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum [Internet]. 2002 [cited 2021 May 24];46(3):654\u201362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11920401\/","DOI":"10.1002\/art.10177"},{"key":"813_CR6","doi-asserted-by":"crossref","unstructured":"Bilginer Y, Topaloglu R, Alikasifoglu A, Kara N, Besbas N, Ozen S et al. Low cortisol levels in active juvenile idiopathic arthritis. Clin Rheumatol [Internet]. 2010 Mar 15 [cited 2019 Jun 29];29(3):309\u201314. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20013015","DOI":"10.1007\/s10067-009-1326-5"},{"key":"813_CR7","doi-asserted-by":"crossref","unstructured":"Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M, Gonzalez-Gay MA. Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum [Internet]. 1997;40(5):859\u201364. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9153547","DOI":"10.1002\/art.1780400513"},{"key":"813_CR8","doi-asserted-by":"crossref","unstructured":"Aeschlimann FA, Batu ED, Canna SW, Go E, G\u00fcl A, Hoffmann P et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis [Internet]. 2018 May 1 [cited 2018 Jun 9];77(5):728\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29317407","DOI":"10.1136\/annrheumdis-2017-212403"},{"key":"813_CR9","doi-asserted-by":"crossref","unstructured":"Hall J, Morand EF, Medbak S, Zaman M, Perry L, Goulding NJ et al. Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum [Internet]. 1994 Aug [cited 2020 Mar 21];37(8):1132\u20137. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8053951","DOI":"10.1002\/art.1780370804"},{"key":"813_CR10","doi-asserted-by":"crossref","unstructured":"Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther [Internet]. 2013 Mar 5 [cited 2018 Mar 16];13(3):361\u201376. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23289865","DOI":"10.1517\/14712598.2013.735657"},{"key":"813_CR11","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol [Internet]. 2004 Feb [cited 2017 May 12];31(2):390\u20132. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14760812"},{"key":"813_CR12","doi-asserted-by":"crossref","unstructured":"Gawlik A, Shmoish M, Hartmann MF, Malecka-Tendera E, Wudy SA, Hochberg Z. Steroid Metabolomic Disease Signature of Nonsyndromic Childhood Obesity. J Clin Endocrinol Metab [Internet]. 2016 Nov 1 [cited 2022 Jun 21];101(11):4329\u201337. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27504851\/","DOI":"10.1210\/jc.2016-1754"},{"key":"813_CR13","doi-asserted-by":"crossref","unstructured":"Wudy SA, Schuler G, S\u00e1nchez-Guijo A, Hartmann MF. The art of measuring steroids: Principles and practice of current hormonal steroid analysis. J Steroid Biochem Mol Biol [Internet]. 2018 May 1 [cited 2021 Apr 7];179:88\u2013103. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28962971\/","DOI":"10.1016\/j.jsbmb.2017.09.003"},{"key":"813_CR14","doi-asserted-by":"publisher","unstructured":"Atzeni F, Straub RH, Cutolo M, Sarzi-Puttini P. Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis. Ann N Y Acad Sci [Internet]. 2010 Apr [cited 2018 Mar 16];1193(1):179\u201381. Available from: https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05366.x","DOI":"10.1111\/j.1749-6632.2009.05366.x"},{"key":"813_CR15","doi-asserted-by":"crossref","unstructured":"Edwards C. Sixty years after Hench\u2013corticosteroids and chronic inflammatory disease. J Clin Endocrinol Metab [Internet]. 2012 May [cited 2020 Mar 21];97(5):1443\u201351. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22378812","DOI":"10.1210\/jc.2011-2879"},{"key":"813_CR16","doi-asserted-by":"crossref","unstructured":"Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet [Internet]. 2014 [cited 2022 Jun 22];29(1):12\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24284432\/","DOI":"10.2133\/dmpk.DMPK-13-RV-119"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00813-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T06:04:55Z","timestamp":1681279495000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00813-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00813-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1092539\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1092539\/v2","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"REB approval for the study was received from Rambam Helsinki Committee (RMB) and all patients signed the informed consent for.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest to disclose and no financial honorarium, grant, or other form of payment was given to anyone to produce the manuscript. The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}